Alopecia Treatment Market- Insights
Alopecia also called as hair-loss or baldness is a medical condition that refers to loss of hairs from head or any part of the body. The condition can occur in both male and female and at any age. There are five major type of alopecia namely; alopecia areata, androgenic alopecia, ciatricial alopecia, traction alopecia, and alopecia totalis. Alopecia areata is a common autoimmune disorder in which the immune system of body attacks the healthy hair follicle leading to hair fall. Androgenic alopecia also known as male pattern baldness and female pattern hair loss is a very common type of alopecia and affects many individuals at some stage of life. Ciatricial alopecia also known as scarring alopecia is a condition in which hair follicles are destroyed and replaced by scar tissue. There are only few approved treatment drugs indicated for the treatment of alopecia. For instance, Minoxidil, Finasteride, and Cyclosporine.
Frequent launch, approvals, and robust pipeline of alopecia treatment products is expected to drive the growth of market
In recent past, regulatory bodies have approved novel drugs for treatment of alopecia and many drugs are in pipeline, which are expected to receive approval in near future. Approval of novel drugs and presence of robust drug pipeline is expected to drive global alopecia treatment market growth in near future. For instance, in January 2018, Concert Pharmaceuticals, Inc., a U.S.-based company received Fast Track designation from U.S. Food and Drug Administration (FDA) for its novel product CTP-543. CTP-543 is a novel, oral Janus kinase (JAK) inhibitor for the treatment of moderate-to-severe alopecia areata. In April 2018, Concert Pharmaceuticals, Inc., finished patient recruitment for Phase 2a trial evaluating CTP-543 for the treatment of moderate-to-severe alopecia areata. In January 2018, HCell Inc., a Texas-based biotechnology company received Orphan Drug Designation (ODD) for HC017AA drug from U.S. Food and Drug Administration (FDA). HC017AA is an underdevelopment drug indicated for non- surgical treatment for Alopecia Areata in Pediatric Patients. In 2016, Galderma Laboratories, L.P., a company focused on development of dermatology and skin health launched its new qilib Hair Regrowth + Revitalization System and qilib Hair Health Reinforcement Biotin + Multivitamin Supplement. The qilib system is indicated for hair regrowth and contains clinically proven, prescription-strength minoxidil specifically formulated for men (5% minoxidil) or women (2% minoxidil). In 2017, Perrigo Company Plc. Launched over-the-counter (OTC) Women's Rogaine 5% minoxidil foam (minoxidil topical aerosol, 5% foam). Women's Rogaine 5% minoxidil foam (minoxidil topical aerosol, 5% foam) is indicated to regrow hair on top of the scalp. The launches of such novel products in market is expected to drive the global alopecia market growth in near future.
The global alopecia treatment market size was valued at US$ 7.4 Bn in 2017, and is expected to witness a CAGR of 5.6% over the forecast period (2018 – 2026).
Figure 1. Global Alopecia Treatment Market Share (%), By Region, 2017
Source: Coherent Market Insights Analysis (2017)
Increasing prevalence of alopecia is expected to propel demand for its treatment drugs
According to the data published by National Center for Biotechnology Information (NCBI), in 2015, androgenetic alopecia is most prevalent autoimmune disorder and the second most prevalent hair loss disorder with around 2% population worldwide suffering from androgenetic alopecia. According the data published by Arch Argent Pediatr, in 2017, the prevalence of Alopecia areata is higher in the age group of 10 and 25 years and around 60% of people under these age group suffers from Alopecia areata. Therefore, high prevalence of alopecia is expected to propel demand for its treatment drugs, which in turn is expected to create a lucrative environment for the global alopecia treatment market growth in near future.
The presence of alternative treatment option for alopecia is expected to be major factor restraining the global alopecia treatment market growth in near future. For instance, methods such as hair transplant surgery, laser and light-based therapies are expected to hinder the growth of market.
Key players operating in the alopecia treatment market include Histogen, Inc., Aclaris Therapeutics, Inc., Concert Pharmaceuticals, Inc., HCell Inc., GlaxoSmithKline Plc., Daiichi Sankyo, Inc., Cipla Limited, and others.
Alopecia also called as hair loss or baldness is very common condition affecting people across the globe. Alopecia can affect people of all gender and at any stage of life, it generally it affects mid-aged generation. For instance, according the data published by Arch Argent Pediatr in 2017, the prevalence of Alopecia areata is high in the age group of 10 and 25 years and around 60% of people under these age group suffer from Alopecia areata.
Product launches, approvals, and robust pipeline of novel products is expected to be the major driver of growth of the global alopecia treatment market. For instance, in 2016, Cellmid Limited, a wholly owned subsidiary, Advangen Limited launched new hair loss product évolis in U.S. market. In May 2018, Histogen, Inc., received approval of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) to study its lead product Hair Stimulating Complex (HSC660) in female diffuse hair loss. HSC660 is an investigational injectable treatment for alopecia and is expected to get FDA approval in near future. Key players in the market are engaged in strategic collaborations for increasing geographic presence in market. For instance, in May 2018, Cellmid Limited signed a collaborative agreement with Beijing Fukangren Bio-pharm Tech Co Ltd. for distribution of its product in Peoples Republic of China. Furthermore, the increasing prevalence of alopecia worldwide is expected to drive the growth of market. For instance, according to the data published by National Center for Biotechnology Information (NCBI), in 2015, androgenetic alopecia is most prevalent autoimmune disorder and the second most prevalent hair loss disorder and around 2% population worldwide is suffering from androgenetic alopecia.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
*Browse 52 market data tables and 49 figures on “Alopecia Treatment Market - Global forecast to 2025”.
Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:
In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.
Coherent Market Insights desk research is based on a principle set of research techniques:
Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:
Preliminary Data Mining
The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.
Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.
Coherent Statistical model
We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:
Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.
This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:
The primary research is conducted with the ecosystem players including, but not limited to:
Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.
Talk to our research consultant to design an exclusive report as per your research needs.
We aim to fulfil client's research demands with tailored research solutions.
We aim to provide research studies in quickest turnaround time and in a much cost effective manner.
We cover each industry from supply and demand side with an aim to provide a most holistic research study.
We strive to provide most accurate and reliable research findings in our research reports.